AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01093014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential low-force and high-force muscle stimulation
Description: Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
Study NCT02767076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional paramedian spinal anesthesia
Description: land mark guided paramedian spinal anesthesia
Study NCT00833365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
Study NCT00833365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
Study NCT04339374 — intervention group
Intervention type: DEVICE
Intervention: Photoacoustic imaging, photoacoustic microscopy
Description: * Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise~* The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers~* The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants
Study NCT04339374 — intervention group
Intervention type: DEVICE
Intervention: Endorectal photoacoustic imaging probe
Description: * Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively.~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants
Study NCT04580901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy
Description: Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
Study NCT03823911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Description: All approved direct-acting antivirals for hepatitis C will be used as the intervention.
Study NCT03823911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: Cardiac MRI to assess for myocardial function and fibrosis
Study NCT03823911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI to assess for myocardial function and fibrosis
Study NCT00258895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAPTACEL®: DTaP
Description: 0.5 mL, Intramuscular
Study NCT00982618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1% Lidocaine 1mg/kg/hr IV drip x 48hr
Study NCT00982618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Block
Description: 0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
Study NCT00982618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA Morphine
Description: PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Study NCT02331004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention for fine motor skills
Description: Implementation of an well known activity to improve the function of upper extremities
Study NCT02331004 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Support to activities of daily living
Description: Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
Study NCT02431663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous administration in continuous
Study NCT02431663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous administration in continuous
Study NCT00834834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
Study NCT00834834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DBT
Description: One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
Study NCT00834834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
Study NCT03532711 — intervention group
Intervention type: DRUG
Intervention: fluorouracil
Description: chemotherapy treated patients
Study NCT03863834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InModeRF
Description: InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
Study NCT04151407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
Study NCT01583712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Description: Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
Study NCT01583712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscope
Description: Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
Study NCT04009577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Description: LEM tablet.
Study NCT04009577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM 10 mg
Description: LEM tablet.
Study NCT03802149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: 90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
Study NCT01703897 — intervention group
Intervention type: DEVICE
Intervention: Manometry and Impedance analysis
Study NCT02165761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE® Hybrid Vascular Graft
Study NCT02165761 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-heparin bonded synthetic graft
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3053102
Description: Administered SC
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide ER
Description: Administered SC
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide ER
Description: Administered SC
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally (PO)
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally (PO)
Study NCT02020616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally (PO)
Study NCT04215471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 Antibody SHR-1316
Description: Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
Study NCT02709863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 1-1.5 MAC, inhalation route, during operation
Study NCT02709863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: 1-1.5 MAC, inhalation route, during operation
Study NCT02709863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 6-10 mg/kg/h, iv infusion, during operation
Study NCT03070483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 5000 IU cholecalciferol with 1000 mg calcium citrate daily
Study NCT01788930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study NCT01788930 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Study NCT00786006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.3
Description: FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
Study NCT00786006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
Study NCT02425917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: neuromuscular electrostimulator
Study NCT02425917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPC-Calf
Description: IPC used on calf with or without geko
Study NCT01036412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Chlorhexidine Gluconate Gel
Description: Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
Study NCT01036412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
Study NCT03209037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study NCT02315469 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Complete pre-operative geriatric assessment
Study NCT02315469 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00658996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofLens DD Toric
Description: daily disposable wear contact lens for 2 weeks
Study NCT00658996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ciba Vision Focus Dailies Toric Contact Lens
Description: daily disposable wear contact lens for 2 weeks
Study NCT01460563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
Study NCT01886482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Description: high protein diet
Study NCT00078507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Re-training
Study NCT00078507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Retraining
Description: Facial Exercises
Study NCT00078507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opening Exercises
Study NCT01407224 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Improve Early Breastfeeding
Description: One arm got only training, another arm training and supervision and third arm without any intervention as control.
Study NCT01407224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve Early Breastfeeding
Description: One arm got only training, another arm training and supervision and third arm without any intervention as control.
Study NCT01407224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improve Early Breastfeeding
Description: One arm got only training, another arm training and supervision and third arm without any intervention as control.
Study NCT03585907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAD
Description: A high fat, low carbohydrate diet
Study NCT02767076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided paramedian spinal anesthesia
Description: real time ultrasound guided paramedian spinal anesthesia
Study NCT04015258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: fresh spanish blueberries
Study NCT04015258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: freeze-dried blueberry powder
Study NCT04015258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry components capsules
Description: encapsulated blueberry components (microcrystalline cellulose powder in actual)
Study NCT01295710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-ATG-F
Description: 20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
Study NCT01295710 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
Study NCT04864691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: endovascular recanalization
Description: to recanalize the occlusion cerebral artery with intravascular intervention
Study NCT04864691 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: endovascular recanalization
Description: to recanalize the occlusion cerebral artery with intravascular intervention
Study NCT01460563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline as same dose as MgSO4 as placebo
Study NCT03585907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MIND
Description: A combination of the Mediterranean and DASH diets
Study NCT04794933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Study NCT01155778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human heparan N-sulfatase (rhHNS)
Study NCT00567476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
Study NCT00567476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Description: Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
Study NCT00567476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting beta 2-adrenergic agonist (LABA)
Description: Fixed dose of LABA as prescribed prior to study entry
Study NCT00567476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting beta 2-adrenergic agonist (SABA)
Description: Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
Study NCT01922219 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
Study NCT03443518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psoas Compartment Block (PCB)
Description: 30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
Study NCT03443518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia infiltration
Description: Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
Study NCT03443518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline 0.9% IV infusion
Description: Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
Study NCT03443518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Description: Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
Study NCT04206228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous iron isomaltoside
Description: The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min).
Study NCT04206228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
Study NCT04685694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: sl 800 mcg misoprostol
Study NCT03994367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High animal protein isolate
Description: Increased dietary protein content from animal protein isolates
Study NCT03994367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High animal protein whole food
Description: Increased dietary protein content from animal protein whole food
Study NCT03994367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein isolate
Description: Increased dietary protein content from plant protein isolates
Study NCT03994367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein whole food
Description: Increased dietary protein content from animal protein whole food
Study NCT00573170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
Study NCT04145492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: Patients will take 90 ug of vitamin K2
Study NCT04145492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (inactive vitamin D)
Description: Patients will take 10 ug of vitamin inactive vitamin D
Study NCT00573170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
Study NCT04145492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 and Cholecalciferol
Description: Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
Study NCT04794933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Study NCT04794933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+ PNF in extremity pattern
Study NCT04794933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns
Study NCT00713011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalat XL
Description: Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
Study NCT00713011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiazac XC
Description: Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
Study NCT01561976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride prolonged release
Description: 1000mg in fasting state
Study NCT01561976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride prolonged release
Description: 1000mg in fed state
Study NCT01561976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride sustained release/Glimepiride
Description: 1000/2mg in fed state